TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2970000

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CA)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Flutamide (F)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 10
Study: 30175904

Group type: EXPERIMENTAL
Intervention: Mobile application intervention for online social networking addiction
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 200
Study: 28095892

Group type: EXPERIMENTAL
Intervention: Chuna manual therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Chuna plus usual care
Number of subjects: 60
Study: 25432081

Group type: EXPERIMENTAL
Intervention: Pazopanib 5 mg/ml instilled 3 times daily (n = 72)
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Pazopanib 5 mg/ml instilled 4 times daily (n = 74)
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Pazopanib 10 mg/ml instilled 2 times daily (n = 73)
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Pazopanib 10 mg/ml instilled 3 times daily (n = 73)
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Pazopanib 10 mg/ml instilled 4 times daily (n = 72)
Number of subjects: 510

Group type: COMPARATOR
Intervention: Ranibizumab injection administered once every 4 weeks (n = 73)
Number of subjects: 510

Group type: COMPARATOR
Intervention: Placebo eye drops instilled 4 times daily (n = 73)
Number of subjects: 510
Study: 23480247

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch
Number of subjects: 0
Study: 21498494

Group type: EXPERIMENTAL
Intervention: Spinal morphine 100 µg + TAP block with bupivacaine 2 mg kg(‐1) (S(M)T(LA))
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Spinal morphine 100 µg + TAP block with saline (S(M)T(S))
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline + TAP block with saline (S(S)T(S))
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline + TAP block with bupivacaine (S(S)T(LA))
Number of subjects: 80
Study: 19468030

Group type: EXPERIMENTAL
Intervention: Dose-Intensive Epirubicin and Cyclophosphamide (DI-EC)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Standard-Dose Chemotherapy (SD-CT)
Number of subjects: 344
Study: 16760197

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg Methylphenidate (MPH)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg Atomoxetine (ATX)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Both MPH and ATX
Number of subjects: 16
Study: 15325327

Group type: EXPERIMENTAL
Intervention: GRIF system (automated test ordering and feedback system)
Number of subjects: 11
Study: 11771637

Group type: EXPERIMENTAL
Intervention: Black confederates present during the event (experimental condition)
Number of subjects: 0

Group type: COMPARATOR
Intervention: White confederates present during the event (control)
Number of subjects: 0
Study: 9483720

Group type: EXPERIMENTAL
Intervention: Continuation ratio model applied to individual responses in a seasonal rhinitis trial.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Markov chain approach for dependence on previous responses.
Number of subjects: 0
Study: 8287660

Group type: EXPERIMENTAL
Intervention: N(G)-monomethyl-L-arginine
Number of subjects: 28
Study: 3162653

Group type: EXPERIMENTAL
Intervention: Cefotetan plus doxycycline
Number of subjects: 68

Group type: COMPARATOR
Intervention: Cefoxitin plus doxycycline
Number of subjects: 68
Study: 31425478

Group type: EXPERIMENTAL
Intervention: Intravitreal ranibizumab treatment (0.5 mg in 0.05 ml via six intravitreal injections over 6 months)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Histopathological analysis
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Genetic analysis
Number of subjects: 7
Study: 31383445

Group type: EXPERIMENTAL
Intervention: Aromatherapy with lavender essential oil
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Aromatherapy with orange essential oil
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no aromatherapy)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Comparison between lavender and orange essential oil
Number of subjects: 90
Study: 28104706

Group type: EXPERIMENTAL
Intervention: Vignettes without a risk score
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Vignettes with a risk score
Number of subjects: 129
Study: 26396095

Group type: EXPERIMENTAL
Intervention: Calcitriol alone
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Calcitriol plus calcium carbonate
Number of subjects: 66

Group type: COMPARATOR
Intervention: Calcium carbonate alone
Number of subjects: 66
Study: 24575644

Group type: EXPERIMENTAL
Intervention: Paroxysmal atrial fibrillation group
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (without AF, with premature ventricular ectopic beats)
Number of subjects: 20
Study: 21237502

Group type: EXPERIMENTAL
Intervention: Atorvastatin (40 mg, two tablets once daily)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study: 18083770

Group type: COMPARATOR
Intervention: Conventional tidal volume (V(T)) of 12 ml/kg without positive end-expiratory pressure (PEEP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Low tidal volume (V(T)) of 6 ml/kg and 10 cmH(2)O PEEP
Number of subjects: 40
Study: 16202482

Group type: EXPERIMENTAL
Intervention: Sibling epsilon4 carriers
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Sibling non-epsilon4 carriers
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control epsilon4 carriers
Number of subjects: 71
Study: 15454803

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (hemoglobin concentration, 70 g/L)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Liberal transfusion strategy (hemoglobin concentration, 100 g/L)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy
Number of subjects: 203

Group type: COMPARATOR
Intervention: Liberal transfusion strategy
Number of subjects: 203
Study: 11688554

Group type: EXPERIMENTAL
Intervention: Test formulation (Nonspi 5R = Np)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Reference formulation (ViskenR = Vs)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both formulations of pindolol
Number of subjects: 21
Study: 8660040

Group type: EXPERIMENTAL
Intervention: Technetium‐99m‐HMPAO labelled white cell scan (Tc‐WCS)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Barium follow through examination (Ba‐FT)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Colonoscopy plus biopsy
Number of subjects: 39
Study: 1516333

Group type: EXPERIMENTAL
Intervention: Metallic balls (Protasul-2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metallic balls (Prostasul-10)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ceramic balls
Number of subjects: 0
Study: 6643396

Group type: EXPERIMENTAL
Intervention: Oral lorazepam (2 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31567166

Group type: EXPERIMENTAL
Intervention: High-Definition Chromoendoscopy with targeted biopsy (HDCE-T)
Number of subjects: 210

Group type: COMPARATOR
Intervention: High-Definition White Light Endoscopy with random biopsy (HDWL-R)
Number of subjects: 210
Study: 28796416

Group type: EXPERIMENTAL
Intervention: Vaniprevir
Number of subjects: 0
Study: 25155750

Group type: EXPERIMENTAL
Intervention: PSAA+PNB
Number of subjects: 331

Group type: COMPARATOR
Intervention: PNB
Number of subjects: 331
Study: 22106853

Group type: COMPARATOR
Intervention: OROS MPH 72 mg/day
Number of subjects: 279

Group type: COMPARATOR
Intervention: OROS MPH 54 mg/day
Number of subjects: 279

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study: 21501093

Group type: EXPERIMENTAL
Intervention: EpiCor(®) (EP) 500 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 19664653

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (screening for ischemic heart disease and advice for healthier lifestyle)
Number of subjects: 9322

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 9322

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 9322
Study: 17874825

Group type: EXPERIMENTAL
Intervention: 150 mg polaprezinc (zinc group)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no supplement)
Number of subjects: 23
Study: 15095954

Group type: EXPERIMENTAL
Intervention: Nocturnal nasal positive pressure ventilation (NNPPV)
Number of subjects: 27
Study: 11520252

Group type: EXPERIMENTAL
Intervention: Bivalent Hib-HB vaccine with DTP, OPV or IPV, DTaP, M-M-R(II)
Number of subjects: 126
Study: 9611360

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Endotracheal Tube (ET)
Number of subjects: 43
Study: 7635034

Group type: EXPERIMENTAL
Intervention: Acarbose (Glucobay‐Bayer)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional oral therapy
Number of subjects: 0
Study: 3289583

Group type: EXPERIMENTAL
Intervention: Topical gentamicin solution
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control (no gentamicin)
Number of subjects: 102
Study: 31394015

Group type: EXPERIMENTAL
Intervention: TJ‐122 (n = 17)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: TJ‐48 (n = 14)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: TJ‐122 and TJ‐48 (n = 19)
Number of subjects: 69

Group type: COMPARATOR
Intervention: No traditional medicines (n = 19)
Number of subjects: 69
Study: 28288833

Group type: EXPERIMENTAL
Intervention: Sleep group (n=20)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Wake group (n=17)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Immediate Test control groups (n=36 total, n=18 each)
Number of subjects: 75
Study: 26105600

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg once daily until progression/unacceptable toxicity)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Gemcitabine/cisplatin (GP) [G 1250 mg/m(2) i.v. days 1 and 8 (3-weekly cycle); P 75 mg/m(2) i.v. day 1, (3-weekly cycle) for up to four cycles]
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 217

Group type: COMPARATOR
Intervention: Gemcitabine/cisplatin (GP)
Number of subjects: 217
Study: 23679567

Group type: EXPERIMENTAL
Intervention: Provision of e-mental health information by text
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: Provision of e-mental health information by film
Number of subjects: 217

Group type: COMPARATOR
Intervention: Provision of no e-mental health information
Number of subjects: 217
Study: 21946486

Group type: EXPERIMENTAL
Intervention: M-Bond (MB)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: M-Bond II (MB II)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Super-Bond C&B (SB)
Number of subjects: 0
Study: 19339531

Group type: EXPERIMENTAL
Intervention: Sealed margins
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Refurbishment
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Repair
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Replacement
Number of subjects: 66

Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 66
Study: 16353141

Group type: EXPERIMENTAL
Intervention: Screening for prostate cancer using PSA tests during the 1st visit
Number of subjects: 58710

Group type: EXPERIMENTAL
Intervention: Screening for prostate cancer using PSA tests during the 2nd visit
Number of subjects: 58710

Group type: EXPERIMENTAL
Intervention: Overall detection rate of high-grade cancers during the 1st visit
Number of subjects: 58710

Group type: EXPERIMENTAL
Intervention: Overall detection rate of high-grade cancers during the 2nd visit
Number of subjects: 58710
Study: 15189589

Group type: EXPERIMENTAL
Intervention: Psychological-state theories (PSTs) about significant others
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Internal structure of PSTs
Number of subjects: 0
Study: 10785873

Group type: EXPERIMENTAL
Intervention: LpL activity in non-obese individuals
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Hepatic lipase activity in non-obese individuals
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: LpL activity in obese individuals
Number of subjects: 83
Study: 8810625

Group type: EXPERIMENTAL
Intervention: Therapeutic lavage
Number of subjects: 5
Study: 1452917

Group type: EXPERIMENTAL
Intervention: Streptokinase treatment
Number of subjects: 618

Group type: COMPARATOR
Intervention: Control group (conventional treatment)
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Streptokinase treatment (anterior infarction)
Number of subjects: 618

Group type: COMPARATOR
Intervention: Control group (anterior infarction)
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Streptokinase treatment (inferior infarction)
Number of subjects: 618

Group type: COMPARATOR
Intervention: Control group (inferior infarction)
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Streptokinase therapy
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Ejection fraction and thallium-201 infarct size
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Ejection fraction
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: Prior myocardial infarction
Number of subjects: 618
Study: 2982266

Group type: EXPERIMENTAL
Intervention: Naloxone (1.4 mg/hr for 3 hours)
Number of subjects: 7
Study: 29327649

Group type: EXPERIMENTAL
Intervention: Dive training with auditory components (speaker and electronic horn)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dive training without auditory components
Number of subjects: 10
Study: 28759321

Group type: EXPERIMENTAL
Intervention: Tetracycline (TE), sulfamethoxazole (STX), and ampicillin (AMP) resistant coliforms
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Cefotaxime (CTX) resistant coliforms
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: CTX-resistant coliforms in humans
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Escherichia coli resistance rates
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Multiresistant isolates
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: CTX-resistant isolates
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: AMP- and vancomycin-resistant enterococci
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Enterococci resistance
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: sulII gene copies
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: tetW genes in cattle vs humans
Number of subjects: 485
Study: 27236772

Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg twice per day (b.i.d.) with dose titration
Number of subjects: 213

Group type: COMPARATOR
Intervention: Placebo titration
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Axitinib 5 mg b.i.d. (nonrandomized patients)
Number of subjects: 213
Study: 24094565

Group type: EXPERIMENTAL
Intervention: CSI-guided control of anesthetic depth
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (clinical monitoring of anesthetic depth)
Number of subjects: 50
Study: 22466511

Group type: EXPERIMENTAL
Intervention: Endobronchial valves treatment
Number of subjects: 289

Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 289
Study: 21250569

Group type: EXPERIMENTAL
Intervention: Acrylic resin polymerized by long cycle with added 2% PTFE
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Acrylic resin polymerized by short cycle with added 2% PTFE
Number of subjects: 40

Group type: COMPARATOR
Intervention: Acrylic resin polymerized by long cycle
Number of subjects: 40

Group type: COMPARATOR
Intervention: Acrylic resin polymerized by short cycle
Number of subjects: 40
Study: 19025646

Group type: EXPERIMENTAL
Intervention: Guided self-help intervention
Number of subjects: 58
Study: 16115790

Group type: EXPERIMENTAL
Intervention: Sonomyography (SMG) using a portable B-mode ultrasound scanner
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Sonomyography (SMG) signals from residual forearms
Number of subjects: 9
Study: 12515575

Group type: EXPERIMENTAL
Intervention: Dimethyl sulfoxide (DMSO)
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Acetylcysteine
Number of subjects: 131

Group type: COMPARATOR
Intervention: DMSO
Number of subjects: 131
Study: 10613428

Group type: EXPERIMENTAL
Intervention: Diet only (DO, N = 9)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Diet and aerobic exercise (DE, N = 9)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (C, N = 11)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 29
Study: 7802571

Group type: EXPERIMENTAL
Intervention: Antibiotic prophylaxis (1 g of cephalothin sodium intravenously 30 minutes before the procedure and 500 mg of cephalexin orally every 6 hours for 3 days after the procedure)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group (no antibiotic therapy)
Number of subjects: 164
Study: 2086420

Group type: EXPERIMENTAL
Intervention: MK-927 (1% and 2%)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MK-417 (1% and 1.8%)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 353833

Group type: EXPERIMENTAL
Intervention: L-tryptophan (2 g) + oxprenolol (80 mg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31172867

Group type: EXPERIMENTAL
Intervention: Tablet computer monitoring of upper limb exercise program
Number of subjects: 10
Study: 31331372

Group type: EXPERIMENTAL
Intervention: High-flow nasal therapy (HFNT) set at 37°C and 60 L/min
Number of subjects: 80

Group type: COMPARATOR
Intervention: Noninvasive ventilation (NIV) applied through a mask with pressure support mode, PEEP set at 3-5 cmH2O, tidal volume between 6-8 ml/kg
Number of subjects: 80
Study: 27223809

Group type: EXPERIMENTAL
Intervention: Varenicline 1 mg b.i.d. for 12 weeks
Number of subjects: 323

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 323
Study: 26110625

Group type: EXPERIMENTAL
Intervention: Balance training included in pulmonary rehabilitation (3 times a week for 6 months)
Number of subjects: 62

Group type: COMPARATOR
Intervention: PR-only group (standard pulmonary rehabilitation for 6 months)
Number of subjects: 62
Study: 23201103

Group type: EXPERIMENTAL
Intervention: Carpentier‐Edwards supraannular aortic valve (CE‐SAV)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Mosaic aortic prosthesis
Number of subjects: 403
Study: 21943027

Group type: EXPERIMENTAL
Intervention: Voclosporin (low-dose)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Voclosporin (medium-dose)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Voclosporin (high-dose)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Tacrolimus (Control)
Number of subjects: 334
Study: 17616470

Group type: EXPERIMENTAL
Intervention: High dissociators
Number of subjects: 100

Group type: COMPARATOR
Intervention: Low dissociators
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High and low dissociators
Number of subjects: 100
Study: 16929627

Group type: EXPERIMENTAL
Intervention: Oralized deaf individuals
Number of subjects: 24

Group type: COMPARATOR
Intervention: Normal listening individuals
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups during clinical activities of mastication and dental compression
Number of subjects: 24
Study: 12620524

Group type: EXPERIMENTAL
Intervention: High-fat, low-carbohydrate oral supplement (16.7% protein, 55.1% fat, 28.2% CHO)
Number of subjects: 60

Group type: COMPARATOR
Intervention: High-carbohydrate diet (15% protein, 20% to 30% fat, and 60% to 70% CHO)
Number of subjects: 60
Study: 11181997

Group type: EXPERIMENTAL
Intervention: BSC plus vinorelbine (days 1 and 8, q 21 days for up to six cycles)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Best supportive care (BSC) alone
Number of subjects: 191

Group type: EXPERIMENTAL
Intervention: BSC plus vinorelbine
Number of subjects: 191
Study: 9926766

Group type: EXPERIMENTAL
Intervention: Scaling and root planing
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pocket reduction through osseous surgery and apically‐positioned flap
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Modified Widman flap
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Modified Widman flap and topical application of saturated citric acid at pH 1 for 3 minutes
Number of subjects: 10

Group type: COMPARATOR
Intervention: All treatment modalities
Number of subjects: 10
Study: 11271288

Group type: EXPERIMENTAL
Intervention: High-sodium lactobionate/raffinose solution
Number of subjects: 40

Group type: COMPARATOR
Intervention: High-potassium lactobionate/raffinose solution
Number of subjects: 40
Study: 2740166

Group type: EXPERIMENTAL
Intervention: Biweekly home visiting
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Weekly home visiting
Number of subjects: 210

Group type: COMPARATOR
Intervention: Monthly home visiting
Number of subjects: 210

Group type: COMPARATOR
Intervention: Control group (no visiting)
Number of subjects: 210
Study: 8031165

Group type: EXPERIMENTAL
Intervention: UFT administration
Number of subjects: 98

Group type: COMPARATOR
Intervention: 5‐FU administration
Number of subjects: 98
Study: 377539

Group type: EXPERIMENTAL
Intervention: Intravenous gentamicin and clindamycin
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study: 29373042

Group type: EXPERIMENTAL
Intervention: Matched message
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Mismatched message
Number of subjects: 602

Group type: COMPARATOR
Intervention: Control message
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Responsive group
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Indifferent group
Number of subjects: 602
Study: 30241686

Group type: EXPERIMENTAL
Intervention: 2g of n3 FAs
Number of subjects: 440
Study: 27107672

Group type: EXPERIMENTAL
Intervention: Baclofen (30-270mg/d)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 24784698

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide (200 μg, bid)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Oral dexamethasone (4 mg, bid)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 23077861

Group type: EXPERIMENTAL
Intervention: Fluoride varnish (Duraphat)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 105
Study: 18839053

Group type: EXPERIMENTAL
Intervention: Metformin (1,700 mg/day)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Lifestyle changes only
Number of subjects: 34
Study: 16893493

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 30